PMID- 34113492
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 2167-8359 (Print)
IS  - 2167-8359 (Electronic)
IS  - 2167-8359 (Linking)
VI  - 9
DP  - 2021
TI  - Biotin-streptavidin-guided two-step pretargeting approach using PLGA for 
      molecular ultrasound imaging and chemotherapy for ovarian cancer.
PG  - e11486
LID - 10.7717/peerj.11486 [doi]
LID - e11486
AB  - BACKGROUND: Ovarian cancer seriously threatens the lives and health of women, and 
      early diagnosis and treatment are still challenging. Pre-targeting is a promising 
      strategy to improve the treatment efficacy of ovarian cancer and the results of 
      ultrasound imaging. PURPOSE: To explore the effects of a pre-targeting strategy 
      using streptavidin (SA) and paclitaxel (PTX)-loaded phase-shifting poly 
      lactic-co-glycolic acid (PLGA) nanoparticles with perfluoro-n-pentane 
      (PTX-PLGA-SA/PFPs) on the treatment and ultrasound imaging of ovarian cancer. 
      METHODS: PTX-PLGA/PFPs were prepared with a single emulsion (O/W) solvent 
      evaporation method and SA was attached using carbodiimide. The encapsulation 
      efficiency of PTX and the release characteristics were assessed with high 
      performance liquid chromatography. The phase-change characteristics of the 
      PTX-PLGA-SA/PFPs were investigated. The anti-carcinoembryonic antigen (CEA) 
      antibody (Ab) was covalently attached to PTX-PLGA/PFPs via carbodiimide to create 
      PTX-PLGA-Ab/PFPs. The targeting efficiency of the nanoparticles and the viability 
      of ovarian cancer SKOV3 cells were evaluated in each group using a microscope, 
      flow cytometry, and cell counting kit 8 assays. RESULTS: THE PTX-PLGA-SA/PFPs 
      were spheres with a size of 383.0 +/- 75.59 nm. The encapsulation efficiency and 
      loading capability of the nanoparticles for PTX were 71.56 +/-  6.51% and 6.57 
      +/- 0.61%, respectively. PTX was burst-released up to 70% in 2-3 d. When irradiated 
      at 7.5 W for 3 min, the PTX-PLGA-SA/PFPs visibly enhanced the ultrasonography 
      images (P < 0.05). At temperatures of 45 degrees C and 60 degrees C the nanoparticles 
      phase-shifted into micro-bubbles and the sizes increased. The binding 
      efficiencies of SA and Ab to the PTX-PLGA/PFPs were 97.16 +/-  1.20% and 
      92.74 +/- 5.75%, respectively. Pre-targeting resulted in a high binding efficacy 
      and killing effect on SKOV3 cells (P < 0.05). CONCLUSIONS: The two-step 
      pre-targeting process can significantly enhance the targeting ability of 
      PTX-loaded PLGA nanoparticles for ovarian cancer cells and substantially improve 
      the therapeutic efficacy. This technique provides a new method for ultrasonic 
      imaging and precise chemotherapy for ovarian cancer.
CI  - (c)2021 Zhou et al.
FAU - Zhou, Hang
AU  - Zhou H
AD  - Ultrasound Medicine Department, Chongqing Key Laboratory of Translational 
      Research for Cancer Metastasis and Individualized Treatment, Chongqing University 
      Cancer Hospital, Chongqing, Shapingba District, China.
FAU - Fu, Jing
AU  - Fu J
AD  - Ultrasound Medicine Department, Chongqing Key Laboratory of Translational 
      Research for Cancer Metastasis and Individualized Treatment, Chongqing University 
      Cancer Hospital, Chongqing, Shapingba District, China.
FAU - Fu, Qihuan
AU  - Fu Q
AD  - Ultrasound Medicine Department, Chongqing Key Laboratory of Translational 
      Research for Cancer Metastasis and Individualized Treatment, Chongqing University 
      Cancer Hospital, Chongqing, Shapingba District, China.
FAU - Feng, Yujie
AU  - Feng Y
AD  - Ultrasound Medicine Department, Chongqing Key Laboratory of Translational 
      Research for Cancer Metastasis and Individualized Treatment, Chongqing University 
      Cancer Hospital, Chongqing, Shapingba District, China.
FAU - Hong, Ruixia
AU  - Hong R
AD  - Ultrasound Medicine Department, Chongqing Key Laboratory of Translational 
      Research for Cancer Metastasis and Individualized Treatment, Chongqing University 
      Cancer Hospital, Chongqing, Shapingba District, China.
FAU - Li, Pan
AU  - Li P
AD  - Ultrasound Department, Chongqing Key Laboratory of Ultrasound Molecular Imaging, 
      The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 
      Yuzhong District, China.
FAU - Wang, Zhigang
AU  - Wang Z
AD  - Ultrasound Department, Chongqing Key Laboratory of Ultrasound Molecular Imaging, 
      The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 
      Yuzhong District, China.
FAU - Huang, Xiaoling
AU  - Huang X
AD  - Department of Ultrasound, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, Yuzhong District, China.
FAU - Li, Fang
AU  - Li F
AD  - Ultrasound Medicine Department, Chongqing Key Laboratory of Translational 
      Research for Cancer Metastasis and Individualized Treatment, Chongqing University 
      Cancer Hospital, Chongqing, Shapingba District, China.
LA  - eng
PT  - Journal Article
DEP - 20210525
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
PMC - PMC8162236
OTO - NOTNLM
OT  - Liquid-gas Phase-shift
OT  - Molecular imaging
OT  - PLGA
OT  - Paclitaxel
OT  - Pre-targeting technology
COIS- The authors declare there are no competing interests.
EDAT- 2021/06/12 06:00
MHDA- 2021/06/12 06:01
PMCR- 2021/05/25
CRDT- 2021/06/11 06:45
PHST- 2020/12/01 00:00 [received]
PHST- 2021/04/27 00:00 [accepted]
PHST- 2021/06/11 06:45 [entrez]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2021/06/12 06:01 [medline]
PHST- 2021/05/25 00:00 [pmc-release]
AID - 11486 [pii]
AID - 10.7717/peerj.11486 [doi]
PST - epublish
SO  - PeerJ. 2021 May 25;9:e11486. doi: 10.7717/peerj.11486. eCollection 2021.